Updated Oct 23, 9:08 PM · 60 sources analyzed
Key Takeaways
Tango/Revolution Medicines combo hit 82% ORR in pancreatic cancer at ESMO 2026 — durability data will determine whether this is practice-changing.
Nektar Therapeutics terminated its Phase 2/3 NKTR-255 post-CAR-T lymphoma study with no data released, narrowing an already thin pipeline.
Sanofi terminated its NK cell engager AML program (SAR443579), adding to a growing list of NK engager clinical setbacks across the industry.
🏆 Winner
Revolution Medicines — Rasonque's 82% ORR in pancreatic cancer in combination with vopimetostat is the clearest positive clinical signal in today's brief and directly strengthens the RVMD investment thesis.
📉 Loser
Nektar Therapeutics — termination of the Phase 2/3 NKTR-255 post-CAR-T program removes a key late-stage asset with no data to partially redeem the setback.
🔭 Watch Next
United Therapeutics is expected to release topline Phase 3 results from the RIN-PF-303 inhaled treprostinil trial in IPF — a high-unmet-need market — likely at ATS or CHEST in 2026 or early 2027.
Tango/Revolution combo hits 82% response in pancreatic cancer
At ESMO 2026 in Madrid, Tango Therapeutics reported that its experimental drug vopimetostat combined with Revolution Medicines' RAS inhibitor Rasonque produced tumor responses in 82% of patients with a specific molecular subset of advanced pancreatic cancer. That response rate, reported from a company-sponsored trial, would be extraordinary in a disease where standard chemotherapy rarely achieves responses above 30–40%. If durability data hold up, this combination could reframe the treatment paradigm for RAS-driven pancreatic cancer and intensify competitive pressure across the RAS inhibitor space.
STAT News ↗Tango Therapeutics / Revolution Medicines
Vopimetostat + Rasonque in Advanced pancreatic cancer (RAS-driven subset)
The combination produced tumor responses in 82% of patients with a specific molecular subset of advanced pancreatic cancer, per topline results reported at ESMO 2026 (Madrid). Full numerical detail — including response duration, PFS, and OS — has not yet been published in a peer-reviewed journal; data were presented at a medical conference and reported by STAT News.
Why it matters
This readout materially strengthens Revolution Medicines' investment thesis for Rasonque as a combination backbone, and gives Tango Therapeutics — a company without an approved product — its most compelling clinical proof point to date. The key unknown is durability: a high ORR that translates poorly into PFS or OS will dampen enthusiasm, so investors should demand a full data cut before revising long-term models.
What to watch
Watch for peer-reviewed publication or a full data presentation with PFS and OS curves — likely at a major GI oncology meeting in early 2027 — and monitor whether Tango or Revolution files for Breakthrough Therapy Designation based on this dataset.
ESMO 2026: RAS Inhibitor Combinations Signal Maturing Pancreatic Cancer Strategy
The Tango/Revolution Medicines combination data presented at ESMO 2026 indicate that dual targeting of RAS pathway nodes can produce response rates in pancreatic cancer that far exceed historical benchmarks for cytotoxic chemotherapy.
Why it matters
For companies developing single-agent KRAS inhibitors in pancreatic cancer, this data raises the competitive bar significantly and may push BD teams toward combination licensing rather than solo development strategies. The ESMO presentation positions both Tango and Revolution as attractive collaboration partners for large pharma seeking a combination anchor.
What to watch
Watch for any partnership or licensing announcements involving vopimetostat or Rasonque at major pharma BD forums in Q4 2026 or Q1 2027, and for competing combination trial initiations from Mirati/BMS, Amgen, or Eli Lilly.
Nektar Therapeutics
NKTR-255 in Relapsed/refractory large B-cell lymphoma (post CAR-T)
The Phase 2/3 randomized, double-blind, placebo-controlled study of NKTR-255 versus placebo following CD19-directed CAR-T therapy was terminated, per ClinicalTrials.gov registry update (NCT05664217). No efficacy or safety data have been released in connection with the termination.
Why it matters
NKTR-255 was one of Nektar's few remaining clinical-stage bets after years of pipeline attrition; its discontinuation raises questions about the company's path to near-term value creation and may accelerate pressure from investors for a strategic reset. Without disclosure of termination rationale, it is unclear whether this reflects a safety, efficacy, or commercial decision — a distinction that matters significantly for assessing the broader IL-15 agonist class.
What to watch
Watch for a Nektar corporate update or SEC filing in the coming weeks disclosing the reason for termination and any pipeline reprioritization, which will be critical for assessing whether the company's remaining assets justify its valuation.
Sanofi
SAR443579 (NK cell engager) in Acute myeloid leukemia and hematological malignancies
The Phase 1/2 randomized, open-label, multi-cohort study of SAR443579 — a natural killer cell engager — in combination with different agents for hematological malignancies was terminated, per ClinicalTrials.gov registry update (NCT06508489). No efficacy or safety outcome data have been disclosed in connection with the termination.
Why it matters
Sanofi's decision to terminate this program — opened as recently as 2024 — suggests either early safety signals or a strategic portfolio decision to redirect resources; for investors watching the NK engager space, this reinforces skepticism about the modality's near-term clinical viability in hematologic malignancies. Sanofi has deep enough pockets to absorb the loss, but smaller NK-focused companies should be monitored for sentiment impact.
What to watch
Watch for any Sanofi pipeline day or investor update that addresses NK cell engager strategy broadly, particularly whether the company exits the modality or pivots to a different NK-cell approach.
The combination produced tumor responses in 82% of patients with a specific molecular subset of advanced pancreatic cancer, per topline results reported at ESMO 2026 (Madrid). Full numerical detail — including response duration, PFS, and OS — has not yet been published in a peer-reviewed journal; data were presented at a medical conference and reported by STAT News.
Why it matters
An 82% ORR (share of patients whose tumors shrank) in pancreatic cancer — one of oncology's most treatment-resistant diseases — would be a landmark efficacy signal that validates the RAS-inhibitor combination approach and puts pressure on every competitor developing KRAS-targeted therapies.
Analysis
This readout materially strengthens Revolution Medicines' investment thesis for Rasonque as a combination backbone, and gives Tango Therapeutics — a company without an approved product — its most compelling clinical proof point to date. The key unknown is durability: a high ORR that translates poorly into PFS or OS will dampen enthusiasm, so investors should demand a full data cut before revising long-term models.
What to watch
Watch for peer-reviewed publication or a full data presentation with PFS and OS curves — likely at a major GI oncology meeting in early 2027 — and monitor whether Tango or Revolution files for Breakthrough Therapy Designation based on this dataset.
The Phase 2/3 randomized, double-blind, placebo-controlled study of NKTR-255 versus placebo following CD19-directed CAR-T therapy was terminated, per ClinicalTrials.gov registry update (NCT05664217). No efficacy or safety data have been released in connection with the termination.
Why it matters
The termination of a Phase 2/3 program in a post-CAR-T setting eliminates one of Nektar's late-stage pipeline assets and narrows the company's already-thin clinical portfolio.
Analysis
NKTR-255 was one of Nektar's few remaining clinical-stage bets after years of pipeline attrition; its discontinuation raises questions about the company's path to near-term value creation and may accelerate pressure from investors for a strategic reset. Without disclosure of termination rationale, it is unclear whether this reflects a safety, efficacy, or commercial decision — a distinction that matters significantly for assessing the broader IL-15 agonist class.
What to watch
Watch for a Nektar corporate update or SEC filing in the coming weeks disclosing the reason for termination and any pipeline reprioritization, which will be critical for assessing whether the company's remaining assets justify its valuation.
The Phase 1/2 randomized, open-label, multi-cohort study of SAR443579 — a natural killer cell engager — in combination with different agents for hematological malignancies was terminated, per ClinicalTrials.gov registry update (NCT06508489). No efficacy or safety outcome data have been disclosed in connection with the termination.
Why it matters
Termination of a multi-cohort NK cell engager program in AML signals another setback for the NK-cell engager modality, which has struggled to translate preclinical promise into clinical results across the industry.
Analysis
Sanofi's decision to terminate this program — opened as recently as 2024 — suggests either early safety signals or a strategic portfolio decision to redirect resources; for investors watching the NK engager space, this reinforces skepticism about the modality's near-term clinical viability in hematologic malignancies. Sanofi has deep enough pockets to absorb the loss, but smaller NK-focused companies should be monitored for sentiment impact.
What to watch
Watch for any Sanofi pipeline day or investor update that addresses NK cell engager strategy broadly, particularly whether the company exits the modality or pivots to a different NK-cell approach.
The multinational Phase 3 study (RIN-PF-303) evaluating inhaled treprostinil against placebo for change in absolute forced vital capacity (FVC) in IPF has been marked Completed on ClinicalTrials.gov (NCT05255991). No efficacy or safety data have been released in connection with the status update.
Why it matters
IPF remains a high-unmet-need market; if inhaled treprostinil demonstrates FVC benefit on top of current antifibrotics, it would offer a new add-on option in a space dominated by nintedanib and pirfenidone.
Analysis
Completion of the registry status is informational only — the critical question is what the data show, and United Therapeutics has not yet disclosed results. The IPF add-on therapy market is competitive and the company will need a meaningful absolute FVC difference, not just statistical significance, to move prescribing behavior.
What to watch
Watch for United Therapeutics to release topline Phase 3 results from RIN-PF-303 at a pulmonary medical meeting — likely ATS or CHEST — in 2026 or early 2027.
The two-part, randomized, double-blind, placebo-controlled Phase 2 study of REC-994 (200 mg and 400 mg) in symptomatic cerebral cavernous malformation has been marked Completed on ClinicalTrials.gov (NCT05085561). No efficacy or safety data have been released in connection with the status update.
Why it matters
CCM is an orphan neurological disease with no approved pharmacotherapy; a positive REC-994 result would validate Recursion's AI-driven drug discovery platform in a clinically meaningful, approvable indication.
Analysis
For Recursion, which has faced skepticism about whether its AI-discovery approach translates into clinical wins, REC-994 is a high-profile test case — completion of the trial without disclosed data leaves investors in the dark at a moment when the company's platform credibility is under scrutiny. The data, when released, will be read as much as a verdict on AI-driven drug discovery as on the drug itself.
What to watch
Watch for Recursion to announce topline Phase 2 results for REC-994 in the near term, and whether the data package supports a Phase 3 advancement decision in CCM.
Computationally Guided Design of Novel PDE4 Inhibitors for Plaque Psoriasis
Researchers used computational methods to design two novel phosphodiesterase-4 (PDE4) inhibitors — enzymes that, when blocked, reduce inflammatory signaling — intended to improve on the efficacy and tolerability profile of existing PDE4 inhibitors for plaque psoriasis.
Why it matters
If the in silico design approach yields candidates with better selectivity or a wider therapeutic window than approved PDE4 inhibitors like apremilast, it could re-open a partially crowded competitive space against IL-17 and IL-23 biologics in moderate-to-severe psoriasis.
Analysis
This is preclinical, preprint-stage work with no in-human data, so commercial relevance is distant — but the dermatology market is large enough that even incremental PDE4 improvements attract partnership interest. Investors in the psoriasis space should track whether these candidates advance to IND-enabling studies, which would be the first meaningful signal of translatability.
What to watch
Watch for peer-reviewed publication and whether the authors or any partnering institution files an IND application for either compound, which would mark the first clinical translation test of this computational design approach.
ESMO 2026: RAS Inhibitor Combinations Signal Maturing Pancreatic Cancer Strategy
The Tango/Revolution Medicines combination data presented at ESMO 2026 indicate that dual targeting of RAS pathway nodes can produce response rates in pancreatic cancer that far exceed historical benchmarks for cytotoxic chemotherapy.
Why it matters
The 82% ORR signals that combination RAS pathway inhibition — pairing a PRMT5 or similar epigenetic modifier with a direct RAS blocker — may be necessary to overcome resistance mechanisms that have limited single-agent KRAS inhibitors, reshaping trial design logic across the RAS inhibitor development field.
Analysis
For companies developing single-agent KRAS inhibitors in pancreatic cancer, this data raises the competitive bar significantly and may push BD teams toward combination licensing rather than solo development strategies. The ESMO presentation positions both Tango and Revolution as attractive collaboration partners for large pharma seeking a combination anchor.
What to watch
Watch for any partnership or licensing announcements involving vopimetostat or Rasonque at major pharma BD forums in Q4 2026 or Q1 2027, and for competing combination trial initiations from Mirati/BMS, Amgen, or Eli Lilly.
Alpha-2 Agonist Sedation Trial in Critical Illness Reaches Completion
The University of Edinburgh's Phase 3 A2B trial, evaluating whether alpha-2 agonist sedation (which keeps ICU patients in a lighter sedation state) produces better clinical outcomes than standard sedation in critically ill mechanically ventilated patients, has completed enrollment and follow-up per ClinicalTrials.gov (NCT03653832).
Why it matters
If A2B demonstrates a meaningful reduction in delirium, ventilator days, or mortality with alpha-2 agonist-based sedation protocols, it would support broader adoption of agents like dexmedetomidine and could influence ICU sedation guidelines that drive institutional formulary decisions.
Analysis
This is a registry completion with no disclosed results, so clinical interpretation is premature — but the critical care sedation market is commercially relevant, and a positive A2B outcome could benefit generic dexmedetomidine suppliers and any branded next-generation alpha-2 agonist in development. The academic nature of this trial means results will likely appear in a high-impact general medical journal rather than a company press release.
What to watch
Watch for publication of A2B trial results in a major critical care or general medicine journal — likely within 12 months of trial completion — which will determine whether alpha-2 agonist sedation becomes standard of care guidance.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
Revolution Medicines' RAS inhibitor Rasonque, in combination with Tango Therapeutics' vopimetostat, produced an 82% tumor response rate in patients with a RAS-driven subset of advanced pancreatic cancer, per data presented at ESMO 2026 in Madrid and reported by STAT News. This is the most consequential clinical signal for Rasonque in a solid tumor combination setting to date.
STAT News ↗